Frankfurt
30.04.26 | 15:25
0,113 Euro
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 24.04. | LEE'S PHARM (00950): NOTIFICATION LETTER TO NON-REGISTERED SHAREHOLDERS AND REPLY FORM | - | HKEx | ||
| 24.04. | LEE'S PHARM (00950): NOTIFICATION LETTER TO REGISTERED SHAREHOLDERS AND REPLY FORM | 2 | HKEx | ||
| 23.04. | LEE'S PHARM (00950): PROXY FORM | - | HKEx | ||
| 23.04. | LEE'S PHARM (00950): NOTICE OF ANNUAL GENERAL MEETING | - | HKEx | ||
| 23.04. | LEE'S PHARM (00950): GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE NEW SHARES, RE-ELECTION OF DIRECTORS AND NOTICE OF ANNUAL GENERAL MEETING | - | HKEx | ||
| LEES PHARMACEUTICAL Aktie jetzt für 0€ handeln | |||||
| 23.04. | LEE'S PHARM (00950): ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2025 | 1 | HKEx | ||
| 23.04. | LEE'S PHARM (00950): ANNUAL REPORT 2025 | - | HKEx | ||
| 30.03. | LEE'S PHARM (00950): FINAL DIVIDEND FOR THE YEAR ENDED 31 DECEMBER 2025 | 1 | HKEx | ||
| 30.03. | Lee's Pharmaceutical Holdings Ltd. Reports Retreat In Full Year Bottom Line | 1 | RTTNews | ||
| 30.03. | LEE'S PHARM (00950): ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2025 | - | HKEx | ||
| 25.03. | LEE'S PHARM (00950): VOLUNTARY ANNOUNCEMENT - APPROVAL OF INTRAROSA BY NMPA | - | HKEx | ||
| 17.03. | LEE'S PHARM (00950): NOTICE OF BOARD MEETING | 5 | HKEx | ||
| 27.01. | LEE'S PHARM (00950): VOLUNTARY ANNOUNCEMENT - FDA APPROVAL OF SUPPLEMENTAL NEW DRUG APPLICATION FOR ADASUVE | - | HKEx | ||
| 22.12.25 | LEE'S PHARM (00950): SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO DISCLOSEABLE TRANSACTION - ACQUISITION OF ASSETS | 5 | HKEx | ||
| 18.12.25 | LEE'S PHARM (00950): PASSING AWAY OF MICHELE DALLA LIBERA | 1 | HKEx | ||
| 11.12.25 | Lee's Pharmaceutical Holdings Limited: Lee's Pharmaceutical Holdings Limited Acquires Staccato One Breath Technology Platform and Assets, Driving Pipeline Expansion and Advancing Global Partnership with UCB Through Acquired Rights | 594 | PR Newswire | Acquisition of Staccato One Breath Technology, a proprietary platform technology with broad therapeutic potentialSynergistic and complementary to Lee's Pharm's existing products pipeline... ► Artikel lesen | |
| 11.12.25 | Lee's Pharmaceutical Holdings Limited Acquires Staccato One Breath Technology Platform and Assets, Driving Pipeline Expansion and Advancing Global Partnership with UCB Through Acquired Rights | 394 | PR Newswire | Acquisition of Staccato® One Breath Technology®, a proprietary platform technology with broad therapeutic potential
Synergistic and complementary to Lee's Pharm's existing products... ► Artikel lesen | |
| 08.12.25 | LEE'S PHARM (00950): DISCLOSEABLE TRANSACTION - ACQUISITION OF ASSETS | 1 | HKEx | ||
| 12.09.25 | Dividendenbekanntmachungen (12.09.2025) | 12.972 | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABSA GROUP LIMITED ADR US00400T1025 0,887 USD 0,7558 EUR ACADIAN ASSET MANAGEMENT INC US10948W1036 0,01 USD 0,0085 EUR ALBEMARLE... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GILEAD SCIENCES | 111,90 | +0,34 % | Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel | FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the successful completion of its previously announced acquisition of Arcellx, Inc. (Nasdaq: ACLX). Under the... ► Artikel lesen | |
| ZOETIS | 98,36 | +0,39 % | Zoetis Gears Up to Report Q1 Earnings: Is a Beat in the Cards? | ||
| SINOPHARM | 2,065 | +0,73 % | SINOPHARM (01099): ANNOUNCEMENT PRINCIPAL UNAUDITED ACCOUNTING DATA AND FINANCIAL INDICATORS OF SINOPHARM ACCORD FOR THE FIRST QUARTER ENDED 31 MARCH ... | ||
| CSPC PHARMA | 0,940 | +2,10 % | CSPC PHARMA Amphotericin B Liposome for Injection Receives EU Marketing Approval | ||
| WUXI BIOLOGICS | 3,575 | -1,65 % | WUXI BIO (02269): SUSTAINABILITY REPORT 2025 | ||
| SHANGHAI FOSUN PHARMACEUTICAL | 2,051 | -3,89 % | Fosun Pharma Announces Q1 2026 Results: Net Profit Attributable to Shareholders After Deducting Non-Recurring Gains and Losses Increased by 21.96% YoY, With Strong Pipeline Execution | SHANGHAI, April 28, 2026 /PRNewswire/ -- On 28 April, Fosun Pharma ("the Company", stock code: 600196.SH; 02196.HK) announced its results for the first quarter... ► Artikel lesen | |
| GEDEON RICHTER | 36,200 | +3,84 % | Richter Reaches Agreement With Foundations on Dividend Payment Schedule | ||
| DR REDDYS | 11,600 | -1,69 % | Dr. Reddy Falls Despite OK From Health Canada | ||
| MEDIPHARM LABS | 0,053 | +0,95 % | Medipharm Labs Corp: Medipharm welcomes U.S. cannabis product restructuring | ||
| ASPEN PHARMACARE | 7,000 | -2,10 % | ASPEN PHARMACARE HOLDINGS LIMITED - Resignation of Executive Director | ||
| SHANGHAI PHARMACEUTICALS | 1,320 | +3,94 % | SH PHARMA 1Q26 Attributable Net Profit Up 6.35% YoY | ||
| LUYE PHARMA | 0,282 | 0,00 % | LUYE PHARMA (02186): ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2025 | ||
| SIHUAN PHARMACEUTICAL HOLDINGS GROUP | 0,138 | -0,72 % | SIHUAN PHARM (00460): NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED HOLDER | ||
| CHINA RESOURCES PHARMACEUTICAL | 0,550 | -0,90 % | CHINARES PHARMA (03320): ANNOUNCEMENT UNAUDITED FINANCIAL RESULTS OF CR PHARMACEUTICAL COMMERCIAL FOR THE THREE MONTHS ENDED 31 MARCH 2026 IN RELATION ... | ||
| HANSOH PHARMACEUTICAL | 3,914 | -3,14 % | HANSOH PHARMA (03692): VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO THE RESTRICTED SHARE UNIT SCHEME |
LEES PHARMACEUTICAL HOLDINGS LTD gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,113 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LEES PHARMACEUTICAL HOLDINGS LTD finden Sie auf Wallstreet Online.